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Abstract
Recent evidence implicates the insulin-like growth factor (IGF) pathway in development of Ewing 
Sarcoma, a highly malignant bone and soft tissue tumor that primarily affects children and young 
adults. Despite promising results from preclinical studies of therapies that target this pathway, 
early phase clinical trials have shown that a significant fraction of patients do not benefit, 
suggesting that cellular factors determine tumor sensitivity. Using FAIRE-seq, a chromosomal 
deletion of the PTEN locus in a Ewing sarcoma cell line was identified. In primary tumors PTEN 
deficiency was observed in a large subset of cases, although not mediated by large chromosomal 
deletions. PTEN loss resulted in hyper-activation of the AKT signaling pathway. PTEN rescue led 
to decreased proliferation, inhibition of colony formation, and increased apoptosis. Strikingly, 
PTEN loss decreased sensitivity to IGF-1R inhibitors but increased responsiveness to 
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temsirolimus, a potent mTOR inhibitor, as marked by induction of autophagy. These results 
suggest that PTEN is lost in a significant fraction of primary tumors and this deficiency may have 
therapeutic consequences by concurrently attenuating responsiveness to IGF-1R inhibition while 
increasing activity of mTOR inhibitors. The identification of PTEN status in the tumors of patients 
with recurrent disease could help guide the selection of therapies.
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Introduction
Ewing sarcoma is a malignant bone and soft tissue tumor primarily affecting children and 
young adults. Despite intensive chemotherapy, surgery and radiation therapy approximately 
50% of patients ultimately succumb to the disease. Ewing sarcoma is characterized by 
chromosomal translocations that fuse a member of the TET family to one of a subset of ETS 
transcription factors (1, 2). Eighty to eighty-five percent of Ewing Sarcoma tumors contain 
t(11;22)(q24;q12) generating an in-frame fusion of EWSR1 to FLI1 (2). The resulting 
chimeric EWS-FLI1 protein is a potent transcriptional modulator that regulates multiple 
genes implicated in malignant transformation (3, 4).
Several lines of evidence support a role for the insulin-like growth factor (IGF) pathway in 
the development of Ewing sarcoma. EWS-FLI1 regulates IGF1 in Ewing sarcoma cell lines 
and is induced by EWS-FLI1 in mesenchymal stem cells (5-7). IGF-1 and its receptor 
(IGF-1R) are expressed in tumors, and IGF-1 expression in cell lines leads to autocrine 
activation (8, 9). IGF-1 signaling is necessary for the survival and proliferation of Ewing 
sarcoma cells (10, 11), transformation of murine fibroblasts by EWS-FLI (12) as well as for 
normal bone development (13). The promising results of preclinical trials targeting IGF 
pathway in Ewing Sarcoma has made it an attractive therapeutic target (14-17). However, 
studies of IGF-1 and IGF-1R inhibitors in early phase clinical trials have shown a limited 
response rate (18-20). A biomarker predictive of individuals who may respond to IGF1-
mediated treatment remains to be identified (21, 22).
IGF-1 bound to IGF-1R initiates a signaling cascade through the PI3K pathway resulting in 
phosphorylation of downstream targets including AKT. Phosphorylation of AKT at 
serine-473 (S473) and threonine-308 (T308) promotes cell cycle progression, cell survival, 
migration, and metabolism through differential interactions with multiple substrates 
including mTOR (23, 24). Signaling through the PI3K pathway is attenuated by PTEN 
through dephosphorylation of PIP3 (25). The loss of PTEN results in increased accumulation 
of PIP3 and AKT activation, which has been associated with poor clinical outcomes (26-28). 
The loss or mutation of PTEN has been demonstrated in a range of cancers (26-30); 
however, the function of PTEN in Ewing sarcoma has yet to be investigated.
Here we describe PTEN loss in Ewing sarcoma and its consequences on IGF and mTOR 
signaling, as well as on biochemical responses to small molecule inhibitors. PTEN 
deficiency augments PI3K signaling to AKT while diminishing cellular responsiveness to 
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IGF inhibition. Interestingly, PTEN loss enhances sensitivity to autophagy induced by 
mTOR inhibition. Together these data suggest how PTEN loss may influence the response 
to biological therapies in Ewing sarcoma.
Materials and Methods
Fluorescent In Situ Hybridization
The RP11-383D9 (D9) and RP11-846G17 (G17) BACs were obtained from the Children’s 
Hospital Oakland Research Institute. Bacterial cultures of both BACs were grown in LB 
with 25 μg/mL chloramphenicol and DNA extracted using Qiagen Plasmid Midi Kit with 
slight modifications (10 mL of Buffer P1, P2, and P3 and DNA was eluted in 1 mL 
increments using prewarmed Buffer QF at 65 °C). Probes were made using 1 μg of BAC 
DNA by nick translation (Abbott Laboratories, cat #32-801300) with Red-dUTP (Abbott, 
cat # 02N34-050) according to manufacturer’s protocol. A Chromosome 10 centromeric 
probe (CEP, Abbott Laboratories) was used as a control. Cell lines were trypsinized, 
washed, and then resuspended in a small volume of PBS. 10 mL of KCl at 37 °C was added 
dropwise with gentle agitation for the first 2 mL. After adding KCl, the solution was mixed 
and placed in a 37 °C water bath for 12 min after which 1 mL of fresh cold 3:1 
methanol:acetic acid (fixative) was added. Cells were collected by centrifugation (10 min, 
1000 RPM) and the pellet was resuspended in 10 mL of fresh cold fixative which was added 
dropwise with gentle agitation for the first 2 mL and incubated at room temperature for 10 
min. This process was repeated twice. BAC and CEP probes were then hybridized to each 
cell line before imaging. PTEN and CEP signals were manually counted from at least 20 
nuclei in five separate fields.
Cell culture and Antibodies
Unless otherwise indicated, EWS502, EWS894, and RD-ES cell lines were cultured in 
RPMI supplemented with 15% fetal bovine serum. A673 and MHH-ES-1 cell lines were 
cultured in RPMI supplemented with 10% fetal bovine serum. SK-ES cells were cultured in 
McCoy’s 5A supplemented with 15% fetal bovine serum. SK-N-MC cells were cultured in 
DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1X nonessential 
amino acids. EWS502 and EWS894 were kindly provided by Dr. Jonathan Fletcher 
(Brigham and Women’s Hospital, Boston) and A673 by Dr. Stephen Lessnick (Univ. of 
Utah). Other cell lines were obtained from the DSMZ (Braunschweig, Germany). HUVEC 
cells (Lifeline Technologies) were cultured in Vasculife Basal Media (Lifeline 
Technologies) supplemented with 10% FBS. CD99 (clone 12E7, Ready-to-use, PA0559, 
Leica Microsystems) and PTEN antibodies (clone 138G6, 9559S, Cell Signaling 
Technology) were used for IHC and IF. AKT (#4691), pAKT T308 (#2965), pAKT S473 
(#4060) and LC3B (#3868), cleaved PARP (#5625) were used for immunoblotting (Cell 
Signaling Technology).
Cell Proliferation, Apoptosis, Soft agar, and Autophagy
pLL5.0-PTEN (which expresses PTEN), pLL5.0-shPTEN (which expresses an shRNA 
directed at PTEN 5’-GTATAGAGCGTGCAGATAG-3’) and pLL5.0-shNS (which 
expresses a non-specific shRNA as a control) were kindly provided by Dr. James Bear 
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(UNC-Chapel Hill). Lentivirus was produced as previously described (31). EWS502 cells 
were transduced with either pLL5.0-PTEN or vector control lentivirus in the presence of 
polybrene (6 μg/mL) for 3 hours, after which media was changed and the cells split for 
proliferation, soft agar assays. Cells were stained with trypan blue and counted using a 
hemocytometer to assay proliferation. For soft agar, 0.6% agar was used as the base layer 
and 0.5% agar as the top layer. The plates were counted manually using ImageJ (NIH). 
Apoptosis was assessed using the Annexin V-Cy3 Apoptosis Detection Kit (Sigma-Aldrich) 
according to the manufacturer’s protocol. Flow cytometry was performed using the CyAn 
ADP (Beckman-Coulter). For assessment of autophagy, three days after lentiviral 
transduction A673 and EWS502 cells were split 1:3 and treated with 20 μM chloroquine for 
3 hours or chloroquine followed by 10 ng/mL temsirolimus (LC Laboratories) for 20 hrs. 
Cells were lysed in CHAPS buffer and extracts were separated by SDS-PAGE.
IGF-1 inhibition
Cells were treated with NVP-AEW541 (Cayman Chemical) and OSI-906 (ChemieTek) at 
the indicated concentrations. Prior to treatment with IGF-1, cells were kept in serum-free 
media for two hours in combination with the IGF-1 inhibitor. Cells were then treated with 
IGF-1 (Cell Signaling Technologies) for 15 min and lysed in RIPA buffer (25 mM Tris-HCl 
pH 7.6, 150 mM NaCl, 1% NP-40, 0.1% SDS) supplemented with 200 mM NaVO4 and 50 
mM NaF. Cell extracts were separated by SDS-PAGE and blotted with anti-phospho AKT 
and imaged (LiCor). For assessment of cell viability, EWS502 cells were transduced with 
lentiviral pLL5.0-PTEN or pLL5.0 as a vector control. 24 hours post infection the cells were 
treated with NVP-AEW541 in complete media. Viability was assayed 72 hours following 
NVP-AEW541 treatment using WST-1 (Roche).
Tissue microarray (TMA) and Cell Line Array (CLA) construction
Pellets from the Ewing sarcoma cell lines were fixed in 10% buffered formalin (SF98-4, 
Fisher Scientific) for 16-24 hours, washed twice in 70% ethanol, clotted in 2% low-melting 
agarose (Fisher), and then embedded in paraffin wax. Blocks were sectioned and stained 
with hematoxylin and eosin (H&E, Hematoxylin 7211, Eosin 7111, Richard-Allan). Three 1 
mm cores were removed and embedded into recipient CLA block. For TMA construction, 
Ewing sarcoma cases (n = 25) and controls (breast carcinoma, and PTEN-deleted sarcoma) 
were selected from The University of North Carolina Surgical Pathology and St. Jude 
Children’s Research Hospital archives under an IRB-approved protocol. Hematoxylin and 
eosin (H&E) stained slides were re-reviewed and representative areas of tumor were marked 
for coring. TMA blocks, containing triplicate 0.6 mm cores per case were constructed. TMA 
and CLA blocks were cut into 4 and 5 micron sections respectively and placed on positively 
charged glass slides.
Immunohistochemistry (IHC) and Immunofluorescence (IF)
TMA and CLA slides were stained with CD99 and PTEN antibodies (Bond fully-automated 
slide staining system, Leica Microsystems). Slides were deparaffinized (Bond, AR9222) and 
hydrated in wash solution (Bond, AR9590). Epitope retrieval (pH 9.0, AR9640, Bond) was 
performed followed by a peroxide blocking step (Bond DS9800). CD99 and PTEN (1:400) 
antibodies were incubated for 15 and 30 minutes, respectively then secondary antibody was 
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applied (polymer, Bond DS9800). Chromogenic detection with 3,3’-diaminobenzidine 
(DAB) and hematoxylin was performed (Polymer Refine Detection, DS9800, Bond). 
Stained slides were dehydrated and mounted. For fluorescent detection, the TSA-Cy5 
reagent (PerkinElmer), Hoechst 33258 (Invitrogen) and ProLong Gold antifade reagent 
(Molecular Probes) were used.
Imaging and digital image analysis
IHC stained TMA sections were digitally imaged (Aperio ScanScope XT, Aperio 
Technologies). High-resolution DAPI and Cy5 IF images were obtained (Aperio ScanScope 
FL). For digital images from IHC slides, Aperio’s Cytoplasmic algorithm was used to 
determine the percentage and intensity of cells positive for PTEN or CD99. A PTEN-deleted 
tumor control was used to set the negative/low positive intensity threshold for the PTEN 
stained TMA slide. IF signal was quantified (Definiens Tissue Studio, version 3.6).
Results
A subset of Ewing Sarcomas lack PTEN
We recently reported widespread alterations in chromatin structure and histone 
modifications in Ewing sarcoma cells using high-throughput sequencing (5). Although the 
experiments performed were intended to detect nucleosome-depleted regions of chromatin, 
background signal from Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE-
seq) typically covers the remainder of the genome mappable by short sequencing read and 
thus offers a genome-wide sampling of DNA content. Unexpectedly, we observed an 
approximately 1 Mb region on chromosome 10 that demonstrated a nearly complete loss of 
FAIRE-seq signal, which we hypothesized to indicate homozygous deletion (Fig. 1A). The 
potential deletion encompassed several genes including the terminal exons of PTEN (Fig. 
1A).
Since deletion of PTEN had yet to be detected in Ewing sarcoma using high throughput 
sequencing approaches, we verified this deletion by fluorescence in situ hybridization 
(FISH) using two probes that overlap the PTEN locus, as well as a control centromeric 
probe. One probe (G17) is fully contained within the deleted region whereas half of the 
second probe (D9) was predicted to hybridize outside the deletion (Fig. 1A). Probes were 
hybridized to seven Ewing sarcoma cell lines (EWS502, EWS894, A673, MHH-ES-1, SK-
ES, RD-ES-1, SK-N-MC) and one control cell line (HUVEC). The absence of signal from 
the G17 probe in EWS502 cells confirmed a homozygous deletion at this region (Fig. 1B). 
Signal from the D9 probe was detected which likely results from hybridization to the 
retained region centromeric to the deletion. Signal was observed for both probes in the other 
Ewing sarcoma and control cell lines. However, EWS894 and SK-N-MC cells exhibited 
PTEN/centromeric probe ratios not equal to one suggesting other cytogenetic aberrations 
involving the long arm or centromere of chromosome 10 (Fig. 1B, C). EWS894 had two 
copies of the PTEN locus but three copies of the centromeric probe whereas one copy of the 
PTEN locus and two copies of the centromeric probe were detected in SK-N-MC. The 
PTEN/centromeric probe ratio was equivalent for the remaining cell lines; MHH-ES-1 and 
RD-ES exhibited triploidy of chromosome 10 (Sup. Fig. 1). Consistent with PTEN 
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chromosomal loss, PTEN protein was absent in EWS502 whereas other Ewing sarcoma cell 
lines showed variable levels (Fig. 1D).
In order to address whether PTEN was similarly lost in primary Ewing sarcoma tumor, we 
generated a tissue microarray consisting of 25 tumors diagnosed as Ewing Sarcoma during 
clinical evaluation. The samples were re-reviewed prior to microarray generation, and 
tumor-specific regions were selected for core preparation. Each tumor was represented in 
triplicate at random positions on the array. Microarray sections were hybridized to both 
FISH probes. For the 20 tumors from which FISH signal was interpretable, homozygous loss 
was not observed however copy number varied across tumors (Sup. Fig 2). Since PTEN 
expression can be affected by mechanisms other than deletion, we analyzed PTEN protein 
levels by immunofluorescence (IF) and immunohistochemistry (IHC). A Ewing sarcoma cell 
line array was generated to validate antibody-mediated detection of PTEN. PTEN detection 
by IHC and IF on the cell line array quantitatively matched detection by Western blotting (r2 
= 0.74, Sup. Fig 3). Because of the diverse age of the samples that contributed to the primary 
tumor array and the evolving criteria for Ewing sarcoma diagnosis, we performed IHC and 
IF for CD99 as confirmation of diagnosis and as a quality control. IHC and IF for CD99 as 
well as PTEN were highly concordant (Sup. Fig 4). After eliminating CD99 negative tumors 
and those with poor staining 15 tumors remained. A wide range of PTEN expression was 
detected by IF among the Ewing sarcoma samples. Three tumors demonstrated significantly 
reduced signal when compared to a PTEN-expressing control breast carcinoma sample and a 
PTEN-deficient undifferentiated sarcoma (Fig. 2A). Histological examination suggested that 
non-tumor cells confounded accurate PTEN quantification. We attempted IF for CD99 to 
specifically identify tumor cells, but due to technical constraints co-staining of PTEN and 
CD99 was not possible. However, using CD99 IHC in adjacent sections, we confirmed the 
IF results. We observed that for one additional tumor (tumor 2, Fig. 2A and B) 55% of the 
cells did not demonstrate PTEN signal (Sup. Fig. 5). Remaining PTEN expression in this 
sample may be related to CD99-negative non-tumor cells or tumor heterogeneity (Fig. 2B). 
These data suggest that PTEN expression is reduced in approximately 25% (4 of 15) of 
Ewing sarcomas, and that the loss of PTEN is primarily through mechanisms other than 
large genomic losses. This observation is consistent with other tumors in which PTEN 
expression is lost due to gene silencing or focal deletions (32-35).
PTEN loss in Ewing sarcoma augments AKT signaling
To determine the effect of PTEN loss on AKT signaling across Ewing sarcoma cell lines we 
examined phosphorylation at S473 and T308. Phosphorylation of these sites is indicative of 
AKT activation (23, 24). Among the cell lines tested, EWS502 had the highest level of 
pAKT (Fig. 3A). Low levels of S473 phosphorylation was also observed in EWS894, SK-
ES, and RD-ES-1 cells. T308 phosphorylation was limited to EWS502. PDK1-associated 
phosphorylation of T308 is associated with full AKT activation (36, 37) and was only 
observed in the absence of PTEN suggesting that AKT activation is augmented by PTEN 
loss. We then ectopically expressed PTEN in EWS502 cells to test the association between 
PTEN levels and activated AKT. Increasing PTEN was associated with a progressive 
decrease in pAKT at S473 and T308 (Fig. 3B) suggesting that AKT activation in EWS502 is 
due in part to PTEN deficiency. To test whether PTEN loss altered IGF-1 sensitivity, we 
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examined dose-dependent stimulation by IGF-1 under serum-free conditions. AKT 
demonstrated baseline phosphorylation in all Ewing sarcoma cell lines. IGF-1 stimulation 
resulted in further AKT activation. However, there was no difference in IGF-1 IC50 (Sup. 
Fig. 6). These data indicate that PTEN levels influence AKT activation but do not result in 
enhanced sensitivity to IGF-1.
The cellular effects of PTEN loss in Ewing sarcoma were examined by testing the effect of 
PTEN on cellular proliferation and anchorage-independent growth. PTEN was transduced 
into EWS502 cells and expression was confirmed by immunoblotting. PTEN expression 
resulted in significantly decreased cellular proliferation (Fig. 3C). To address whether the 
reduction in cell proliferation following PTEN expression could be attributed to increased 
apoptosis, we assayed annexin V reactivity by flow cytometry and observed a significant 
increase relative to control cells (Fig. 3D). We also observed a similar increase in cleaved 
PARP (Sup. Fig. 7). Anchorage-independent growth as assayed by colony formation in soft 
agar was also greatly diminished (Fig. 3E). Taken together, these data demonstrate that 
PTEN loss enhances cellular properties associated with transformation in Ewing sarcoma 
cells.
PTEN loss decreases sensitivity to IGF-1 inhibition
Since clinical trials of IGF-1-targeted inhibitors have demonstrated robust but limited patient 
responses, we asked whether PTEN loss might mitigate the effect of these compounds in 
Ewing sarcoma cells. Ewing sarcoma cells were treated with two IGF-1R inhibitors, NVP-
AEW541 (38) and OSI-906 (39). NVP-AEW541 has been tested for Ewing sarcoma 
whereas OSI-906 is an investigational agent for a variety of cancers (15, 16, 39-42). Cells 
cultured in serum-free media were pretreated with these inhibitors prior to stimulation by 
IGF-1. PTEN loss was associated with increased IC50 to the IGF-1 inhibitors as measured 
by AKT activation (Fig. 4A). This differential sensitivity was detectable by phosphorylation 
at both S473 and T308. Interestingly, intermediate sensitivity to these inhibitors was 
observed for EWS894 and SK-ES, both of which demonstrated lower PTEN levels and 
detectable pAKT-S473.
We then examined the effect of PTEN expression on IGF-1R inhibition focusing on NVP-
AEW541 due to its selectivity for IGF-1R (38). Transduced PTEN resulted in enhanced 
sensitivity for NVP-AEW541 with an IC50 approximating the other PTEN-expressing 
Ewing sarcoma cells (Fig. 4B). The enhanced sensitivity for NVP-AEW541 was associated 
with increased cellular toxicity (Fig. 4C). These data suggest that PTEN loss in Ewing 
sarcoma diminishes the efficacy of IGF-1R inhibitors on PI3K signaling as well as viability.
PTEN loss enhances response to temsirolimus
AKT signaling acts on the mTOR pathway to influence multiple cellular processes including 
autophagy (43, 44). In light of the emerging role of mTOR inhibition in Ewing sarcoma 
treatment, we examined the relationship between PTEN loss and autophagic response to the 
mTOR inhibitor, temsirolimus. Ewing sarcoma cells were treated with temsirolimus and 
autophagy was assayed by quantification of LC3BII, a protein localized to autophagosome 
membranes that is generated during autophagy (45). The assay was performed in the 
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presence of chloroquine to inhibit lysosomal processing and thus enable assessment of 
autophagy without ongoing degradation. PTEN-expressing Ewing sarcoma cells (A673) 
demonstrated minimal LC3BII induction in response to chloroquine or to chloroquine and 
temsirolimus (Fig. 5A). In contrast, EWS502 cells demonstrated a modest induction of 
LC3BII in response to chloroquine, but this response was significantly increased by 
temsirolimus (Fig. 5B). Since EWS502 but not A673 cells demonstrated induction of 
temsirolimus-induced autophagy, we examined the effect of modulating PTEN. Silencing 
PTEN in A673 cells augmented the autophagic response to temsirolimus whereas exogenous 
PTEN expression in EWS502 eliminated the effect of temsirolimus (but not chloroquine) 
(Fig. 5A, B). We then examined the effect of inhibiting autophagy with chloroquine on 
cellular viability. Interestingly, treatment with chloroquine attenuated the toxic effects of 
temsirolimus in the absence of PTEN but this difference was lost when PTEN was 
expressed. (Sup. Fig. 8). Together these experiments demonstrate that PTEN expression in 
Ewing sarcoma cells influences autophagic response to temsirolimus with PTEN loss 
associated with increased responsiveness to mTOR inhibition. Further, the induction of 
autophagy by temsirolimus is associated with decreased viability, suggesting that autophagy 
partially mediates the effects of temsirolimus.
Discussion
The unexpected identification of PTEN deletion in a Ewing Sarcoma cell line led us to 
explore the status of PTEN in primary tumors. Although we were unable to detect a similar 
deletion in other cell lines or a set of primary tumors using FISH, quantitative assessment of 
PTEN expression by IHC and IF suggested that approximately 25% of Ewing sarcoma 
tumors are PTEN deficient. Small deletions and other mutations undetectable by FISH, in 
addition to gene silencing, remain alterative mechanisms that result in PTEN loss in Ewing 
sarcoma. However, our observation of PTEN loss is consistent with a recent study that used 
high resolution SNP arrays to examine copy number variation in Ewing sarcoma and 
observed PTEN deletion in 14% of the tumors (46).
We found that PTEN deficiency leads to enhanced AKT activation associated with 
decreased apoptosis, increased proliferation, and anchorage-independent growth. Enhanced 
properties associated with cellular transformation in Ewing sarcoma could result in a more 
aggressive tumor phenotype. Intriguingly, ETS deregulation may cooperate with PTEN loss 
to accelerate tumorigenesis (47). Several lines of evidence indicate that mTOR contributes 
to PTEN-dependent negative feedback regulation of AKT (reviewed in (48) (49)). The loss 
of PTEN in Ewing sarcoma may be one mechanism mediating hyperactivation of AKT even 
in the absence of growth factors such as IGF-1. In addition to potentially contributing to a 
more transformed phenotype, hyperactivation of AKT may decrease sensitivity of Ewing 
sarcoma cells to chemotherapy (50, 51).
We have demonstrated that loss of PTEN decreases sensitivity to IGF-1R inhibition, as 
measured by AKT phosphorylation. Of the limited number of available cell lines tested, 
there were varying degrees of response to IGF-1R inhibition. An intermediate effect was 
seen in two cell lines with reduced PTEN expression and increased AKT phosphorylation. 
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These findings are consistent with a prior study demonstrating that PTEN silencing in 
cultured glioblastoma decreased response to NVP-AEW541 (52).
PTEN loss led to increased sensitivity to temsirolimus treatment as marked by the activation 
of autophagy. Autophagy is a metabolic recycling process in which cellular components are 
broken down in times of stress to maintain metabolic homeostasis. The role of autophagy in 
cancer is complex. Our results suggest that autophagy is required to mediate the cell 
viability effects of mTOR inhibition by temsirolimus. These data are in agreement with 
studies indicating that induction of excessive autophagy can lead to cell death (53, 54). 
mTOR inhibitors may constitute a promising therapeutic class for cancers lacking functional 
PTEN by inducing autophagy-mediated apoptosis.
PTEN deficiency renders cells less sensitive to IGF-1R inhibition but increases autophagic 
response to mTOR inhibition. The differential response to AKT/mTOR pathway 
manipulation has therapeutic implications. The promise of personalized therapy for cancer 
depends on the identification of genetic alterations in specific tumors. The limited efficacy 
of IGF-1R inhibition offers an opportunity for the application of relevant biomarkers. Our 
results indicate that loss of PTEN expression may diminish the therapeutic response of 
Ewing sarcoma to IGF-1R inhibitors. However, our study also suggests a reciprocal 
interaction between PI3K/AKT signaling and autophagy. Whereas PTEN loss decreased 
sensitivity to IGF-1R inhibition, it enhanced sensitivity to temsirolimus. These data suggest 
that patients who are unresponsive to IGF-1R inhibition may benefit from mTOR 
inactivation. The application of PTEN expression as a biomarker to future clinical trial 
would be needed to directly assess this possibility. Due to interactions between the IGF-1R 
and mTOR pathways, combination of IGF-1R- and mTOR-directed therapies are being 
evaluated in preclinical and early phase clinical trials with evidence of efficacy. (55-58). The 
ability to identify and apply relevant prognostic biomarkers during the selection of 
biologically active therapies may greatly increase the possibility of therapeutic benefit.
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PTEN status in Ewing sarcoma affects cellular responses to IGF-1 and mTOR-directed 
therapy; thus, justifying its consideration as a biomarker in future clinical trials.
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Figure 1. Identification of PTEN deletion in Ewing Sarcoma
A, FAIRE-seq derived high throughput sequencing tag density around the PTEN locus in 
EWS502. Red bars indicate the regions of hybridization for the FISH probes. Only genes 
located within the deletion are shown. B, PTEN FISH for representative Ewing sarcoma cell 
lines and a control (HUVEC). Chromosome 10 centromeric probe (green) and PTEN BAC 
probes (red) are shown. C, Observed ratio of PTEN probe to centromeric probe (CEP) 
signal. Error bars indicate standard deviation of PTEN/CEP probe ratio from five unique 
fields counting a minimum of 20 cells per field (with the exception of SK-ES in which 20 
nuclei were analyzed). D, Immunoblot of PTEN in Ewing sarcoma cells. Extracts of 
EWS502, EWS894, A673, MHH-ES-1, SK-ES, RD-ES, and SK-N-MC and a control cell 
line, HUVEC were blotted with anti-PTEN antibody. Tubulin was used as a loading control.
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Figure 2. Loss of PTEN expression in primary Ewing Sarcoma
A, PTEN and CD99 immunofluorescence in Ewing sarcoma. Average immunofluorescence 
(H-score) for PTEN (blue bars) and CD99 (red bars) in Ewing sarcoma and control tumors. 
Positive (+) and negative (−) PTEN control tumors are shown to the right. Error bars 
represent standard deviation of H-scores between replicate cores. Absence of error bars 
indicates single core available for analysis. B, Representative hematoxylin and eosin (H&E), 
CD99, and PTEN diaminobenzidine (DAB) staining. Immunohistochemistry for selected 
Ewing sarcoma and control tumors (indicated in A) is shown. Scale bar, 50 μm.
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Figure 3. PTEN loss enhances AKT signaling promoting transformation
A, Immunoblot for total and phospho-AKT. Ewing cell lines and HUVEC under normal 
growth conditions were immunoblotted for phospho-AKT at S473 and T308. B, PTEN 
expression abrogates phospho-AKT. EWS502 were transduced with increasing amounts of 
PTEN-expressing lentivirus. Extracts were immunoblotted for PTEN, AKT, pAKT S473, 
pAKT T308, and tubulin. Phospho- and total AKT were quantified. The ratio of pAKT/AKT 
is shown (bottom). C, PTEN expression reduces cell proliferation. EWS502 were transduced 
with PTEN on day 0 and cells were counted daily. D, PTEN expression increases apoptosis. 
Annexin V staining in EWS502 cells transduced with PTEN (black) or a control vector 
(grey) were analyzed by flow cytometry. Percentages of annexin positive cells are shown. E, 
PTEN expression reduces colony formation. EWS502 transduced with PTEN or control 
vector were plated in soft agar. Colonies were stained with MTT for visualization (left) and 
quantified (right). Colonies greater than 1 mm in size were counted. For each panel, error 
bars represent standard error between triplicates. * and ** indicate p < 0.05 and p < 0.01 
respectively (two-tailed T-test).
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Figure 4. PTEN modulates sensitivity to IGF-1R inhibitors
A, PTEN loss decreases sensitivity to IGF-1R inhibitors. Ewing Sarcoma cells were treated 
with NVP-AEW541 (left) or OSI-906 (right) at the indicated concentrations for 2 hours in 
serum-free media and then stimulated with IGF-1 (5 ng/mL final concentration) for 15 min. 
Extracts were immunoblotted for pAKT at Thr 308 (top) and S473 (bottom) and results were 
quantified. Relative inhibition was calculated by normalizing pAKT signal to mock 
treatment (zero concentration). B, PTEN expression increases sensitivity to IGF-1R 
inhibition. EWS502 transduced with PTEN (dotted grey) or a control vector (solid black) 
were exposed to NVP-AEW541 for 2 hours in serum-free media and then stimulated with 
IGF-1 (5 ng/mL final concentration) for 15 min. Relative inhibition was calculated as above. 
C, PTEN expression increases the cellular toxicity associated with NVP-AEW541 treatment. 
EWS502 cells were transduced as in B and treated with NVP-AEW541 for 72 hours at 
indicated concentrations and assayed for viability. For each panel, error bars represent 
standard error between replicates. * and ** indicate p < 0.05 and p < 0.01 respectively (two-
tailed T-test).
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Figure 5. PTEN loss potentiates temsirolimus-induced autophagy
A, PTEN silencing enhances induction of autophagy in response to temsirolimus. A673 cells 
transduced with a PTEN-shRNA (shPTEN) or nonspecific control (shNS) were treated with 
chloroquine (CQ) alone or chloroquine and temsirolimus (10 ng/mL) for 20 hours (CQ/TM). 
Chloroquine was added 3 hours prior to the initiation of temsirolimus treatment. Cell 
extracts were immunoblotted for LC3B, PTEN, and tubulin (top). LC3BII bands were 
quantified and normalized to tubulin (bottom). B, PTEN expression abrogates induction of 
autophagy in response to temsirolimus treatment. EWS502 cells transduced with exogenous 
PTEN or a control vector (GFP) were treated with chloroquine (CQ) alone or chloroquine 
and temsirolimus (10 ng/mL) (CQ/TM) as described above. Cell extracts were 
immunoblotted and quantified as above. * and ** indicate p < 0.05 and p < 0.01 respectively 
by two-tailed T-test.
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